Review



bf738735  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress bf738735
    (a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds <t>BF738735,</t> Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).
    Bf738735, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bf738735/product/MedChemExpress
    Average 93 stars, based on 5 article reviews
    bf738735 - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "A high-throughput cell-based platform for Rhinovirus C research and antiviral drug discovery"

    Article Title: A high-throughput cell-based platform for Rhinovirus C research and antiviral drug discovery

    Journal: bioRxiv

    doi: 10.1101/2025.10.28.680218

    (a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds BF738735, Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).
    Figure Legend Snippet: (a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds BF738735, Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).

    Techniques Used: Infection, Antiviral Assay, Inhibition, Virus, Control

    (a) Schematic of 384-well format antiviral assay procedure. Created with BioRender. (b) Assay robustness in 384-well format across RV-A16, RV-B14, and RV-C15a-mGL assays using >100 pre-spotted plates with reference compounds. (c) Distribution of pIC 50 values (-log 10 IC 50 , M) for BF738735 and Rupintrivir in the RV-C15a-mGL assay. Each dot represents an individual run; boxes indicate median, interquartile range (IQR), and whiskers (1.5x IQR).
    Figure Legend Snippet: (a) Schematic of 384-well format antiviral assay procedure. Created with BioRender. (b) Assay robustness in 384-well format across RV-A16, RV-B14, and RV-C15a-mGL assays using >100 pre-spotted plates with reference compounds. (c) Distribution of pIC 50 values (-log 10 IC 50 , M) for BF738735 and Rupintrivir in the RV-C15a-mGL assay. Each dot represents an individual run; boxes indicate median, interquartile range (IQR), and whiskers (1.5x IQR).

    Techniques Used: Antiviral Assay

    (a) Workflow of RV-C15a-mGL HTS campaign in 384-well format. (b) Scatterplot summarizing primary screening at 10 µM and three reference compounds BF738735, Pirodavir, and Rupintrivir (yellow). Compounds with inhibition > 60% and viability > 90% are highlighted in green. (c) Assay performance across 32 HTS plates. VC and CC are plotted against the left Y-axis in % infection, while Z’ is plotted against the right Y-axis. VC, virus control. CC, cell control. (d) Inhibition and viability curves for five top hit compounds from mini dose-response assays (0.2 – 25 µM, n=4). (e) Distribution of IC 50 , CC 50 , and selective index (SI = CC 50 /IC 50 ) values for 19 confirmed hits from mini dose-response assays. Five top hits (SI > 7) are highlighted in green.
    Figure Legend Snippet: (a) Workflow of RV-C15a-mGL HTS campaign in 384-well format. (b) Scatterplot summarizing primary screening at 10 µM and three reference compounds BF738735, Pirodavir, and Rupintrivir (yellow). Compounds with inhibition > 60% and viability > 90% are highlighted in green. (c) Assay performance across 32 HTS plates. VC and CC are plotted against the left Y-axis in % infection, while Z’ is plotted against the right Y-axis. VC, virus control. CC, cell control. (d) Inhibition and viability curves for five top hit compounds from mini dose-response assays (0.2 – 25 µM, n=4). (e) Distribution of IC 50 , CC 50 , and selective index (SI = CC 50 /IC 50 ) values for 19 confirmed hits from mini dose-response assays. Five top hits (SI > 7) are highlighted in green.

    Techniques Used: Inhibition, Infection, Virus, Control



    Similar Products

    bf738735  (MedChemExpress)
    93
    MedChemExpress bf738735
    (a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds <t>BF738735,</t> Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).
    Bf738735, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bf738735/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    bf738735 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    bf738735  (Tocris)
    94
    Tocris bf738735
    (a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds <t>BF738735,</t> Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).
    Bf738735, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bf738735/product/Tocris
    Average 94 stars, based on 1 article reviews
    bf738735 - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    pi4kb inhibitor bf738735  (MedChemExpress)
    93
    MedChemExpress pi4kb inhibitor bf738735
    (a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds <t>BF738735,</t> Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).
    Pi4kb Inhibitor Bf738735, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pi4kb inhibitor bf738735/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    pi4kb inhibitor bf738735 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    compound 9 bf738735  (BioFocus DPI)
    90
    BioFocus DPI compound 9 bf738735
    (a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds <t>BF738735,</t> Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).
    Compound 9 Bf738735, supplied by BioFocus DPI, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/compound 9 bf738735/product/BioFocus DPI
    Average 90 stars, based on 1 article reviews
    compound 9 bf738735 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds BF738735, Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).

    Journal: bioRxiv

    Article Title: A high-throughput cell-based platform for Rhinovirus C research and antiviral drug discovery

    doi: 10.1101/2025.10.28.680218

    Figure Lengend Snippet: (a) Infection kinetics of RV-C15a-mGL in HeLa-CDHR3 C529Y mono29 cells at different MOIs and time points. Data are presented as mean ± SD (n=3). Selected MOI for antiviral assay is highlighted in green. (b) Pilot RV-C15a-mGL antiviral assay with reference compounds BF738735, Pirodavir, and Rupintrivir. Compounds were tested in 8-point dose-response assays starting at 1 µM. Assay plates were fixed at 3 dpi and analyzed by HCI. One representative plate is shown. Each point on the inhibition curves represents an individual replicate. Two operators performed the assay independently (total n=4). VC, virus control. CC, cell control. (c) Virus yield reduction assay with Rupintrivir and Vapendavir. Viral RNA in supernatants was quantified at 72 hpi. Data are mean ± SD (n=3). (d, e) Proof-of-concept inter-operator assay reproducibility across >300 plates containing pre-spotted reference compounds in assays with RV-A16, RV-B14, and RV-C15a-mGL. (f) Representative images of RV-C11a-mGL and RV-C41a-mGL infection and antiviral assays with Rupintrivir (n=3).

    Article Snippet: Rupintrivir (Sigma-Aldrich PZ0315), BF738735 (MedChemExpress HY-U00426), Pirodavir (Sigma-Aldrich SML1818), and Vapendavir (Cayman 30546) were prepared as 10 mM DMSO stocks.

    Techniques: Infection, Antiviral Assay, Inhibition, Virus, Control

    (a) Schematic of 384-well format antiviral assay procedure. Created with BioRender. (b) Assay robustness in 384-well format across RV-A16, RV-B14, and RV-C15a-mGL assays using >100 pre-spotted plates with reference compounds. (c) Distribution of pIC 50 values (-log 10 IC 50 , M) for BF738735 and Rupintrivir in the RV-C15a-mGL assay. Each dot represents an individual run; boxes indicate median, interquartile range (IQR), and whiskers (1.5x IQR).

    Journal: bioRxiv

    Article Title: A high-throughput cell-based platform for Rhinovirus C research and antiviral drug discovery

    doi: 10.1101/2025.10.28.680218

    Figure Lengend Snippet: (a) Schematic of 384-well format antiviral assay procedure. Created with BioRender. (b) Assay robustness in 384-well format across RV-A16, RV-B14, and RV-C15a-mGL assays using >100 pre-spotted plates with reference compounds. (c) Distribution of pIC 50 values (-log 10 IC 50 , M) for BF738735 and Rupintrivir in the RV-C15a-mGL assay. Each dot represents an individual run; boxes indicate median, interquartile range (IQR), and whiskers (1.5x IQR).

    Article Snippet: Rupintrivir (Sigma-Aldrich PZ0315), BF738735 (MedChemExpress HY-U00426), Pirodavir (Sigma-Aldrich SML1818), and Vapendavir (Cayman 30546) were prepared as 10 mM DMSO stocks.

    Techniques: Antiviral Assay

    (a) Workflow of RV-C15a-mGL HTS campaign in 384-well format. (b) Scatterplot summarizing primary screening at 10 µM and three reference compounds BF738735, Pirodavir, and Rupintrivir (yellow). Compounds with inhibition > 60% and viability > 90% are highlighted in green. (c) Assay performance across 32 HTS plates. VC and CC are plotted against the left Y-axis in % infection, while Z’ is plotted against the right Y-axis. VC, virus control. CC, cell control. (d) Inhibition and viability curves for five top hit compounds from mini dose-response assays (0.2 – 25 µM, n=4). (e) Distribution of IC 50 , CC 50 , and selective index (SI = CC 50 /IC 50 ) values for 19 confirmed hits from mini dose-response assays. Five top hits (SI > 7) are highlighted in green.

    Journal: bioRxiv

    Article Title: A high-throughput cell-based platform for Rhinovirus C research and antiviral drug discovery

    doi: 10.1101/2025.10.28.680218

    Figure Lengend Snippet: (a) Workflow of RV-C15a-mGL HTS campaign in 384-well format. (b) Scatterplot summarizing primary screening at 10 µM and three reference compounds BF738735, Pirodavir, and Rupintrivir (yellow). Compounds with inhibition > 60% and viability > 90% are highlighted in green. (c) Assay performance across 32 HTS plates. VC and CC are plotted against the left Y-axis in % infection, while Z’ is plotted against the right Y-axis. VC, virus control. CC, cell control. (d) Inhibition and viability curves for five top hit compounds from mini dose-response assays (0.2 – 25 µM, n=4). (e) Distribution of IC 50 , CC 50 , and selective index (SI = CC 50 /IC 50 ) values for 19 confirmed hits from mini dose-response assays. Five top hits (SI > 7) are highlighted in green.

    Article Snippet: Rupintrivir (Sigma-Aldrich PZ0315), BF738735 (MedChemExpress HY-U00426), Pirodavir (Sigma-Aldrich SML1818), and Vapendavir (Cayman 30546) were prepared as 10 mM DMSO stocks.

    Techniques: Inhibition, Infection, Virus, Control